{"id":"double-blind-adalimumab","safety":{"commonSideEffects":[{"rate":"12-20","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"2-4","effect":"Serious infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By preventing TNF-α from binding to its receptors on immune cells, it suppresses the inflammatory cascade and reduces disease activity. This mechanism is effective across multiple chronic inflammatory conditions.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:54.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"}]},"trialDetails":[{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT07151937","phase":"PHASE2","title":"A Study of LAD191 in Adults With Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2025-09","conditions":"Hidradenitis Suppurativa","enrollment":200},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT01385826","phase":"PHASE2, PHASE3","title":"Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06-29","conditions":"Uveitis, Juvenile Arthritis","enrollment":34},{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT05299242","phase":"PHASE2, PHASE3","title":"The Anti-Freaze-F Study- \"Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study\"","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-21","conditions":"Frozen Shoulder","enrollment":9},{"nctId":"NCT06242652","phase":"PHASE2","title":"A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-03-19","conditions":"Ankylosing Spondylitis","enrollment":250},{"nctId":"NCT05640245","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-12-13","conditions":"Arthritis, Psoriatic","enrollment":207},{"nctId":"NCT05495568","phase":"PHASE3","title":"To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-11-07","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":367},{"nctId":"NCT03180957","phase":"PHASE2","title":"Repurposing Anti-TNF for Treating Dupuytren's Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-03-02","conditions":"Dupuytren's Disease","enrollment":140},{"nctId":"NCT06333210","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2023-12-25","conditions":"Axial Spondyloarthritis","enrollment":421},{"nctId":"NCT05322473","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-04-25","conditions":"Hidradenitis Suppurativa","enrollment":234},{"nctId":"NCT06291948","phase":"PHASE1","title":"A Clinical Study With Adalimumab Biosimilar","status":"COMPLETED","sponsor":"Laboratorios Richmond S.A.C.I.F.","startDate":"2022-08-01","conditions":"Pharmacokinetics, Safety Issues","enrollment":150},{"nctId":"NCT05073315","phase":"PHASE3","title":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-10-04","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT02660580","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2016-02-16","conditions":"Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":443},{"nctId":"NCT06005532","phase":"PHASE3","title":"Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®","status":"UNKNOWN","sponsor":"Mabscale, LLC","startDate":"2023-10-02","conditions":"Plaque Psoriasis","enrollment":494},{"nctId":"NCT03759288","phase":"PHASE2, PHASE3","title":"An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2018-12-07","conditions":"Crohn's Disease, IBD","enrollment":89},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT05020730","phase":"PHASE2","title":"Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa","status":"UNKNOWN","sponsor":"Phoenicis Therapeutics","startDate":"2022-05-05","conditions":"Hidradenitis Suppurativa","enrollment":50},{"nctId":"NCT05372939","phase":"PHASE2","title":"Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)","status":"COMPLETED","sponsor":"Applied Molecular Transport","startDate":"2021-02-05","conditions":"Ulcerative Colitis","enrollment":51},{"nctId":"NCT05172817","phase":"PHASE2, PHASE3","title":"Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients","status":"UNKNOWN","sponsor":"Institute for Developing Science and Health Initiatives, Bangladesh","startDate":"2021-06-02","conditions":"Pharmacokinetics, Safety, Efficacy","enrollment":200},{"nctId":"NCT04115748","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-12-03","conditions":"Psoriatic Arthritis","enrollment":67},{"nctId":"NCT03357939","phase":"PHASE1","title":"Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-01-12","conditions":"Immune System Disorder","enrollment":220},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT02472912","phase":"PHASE1","title":"Adalimumab PK Bioequivalence Study to EU and US Sourced Humira","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":270},{"nctId":"NCT04705844","phase":"PHASE3","title":"Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)","status":"WITHDRAWN","sponsor":"Alachua Government Services, Inc.","startDate":"2021-09","conditions":"Mild to Moderate COVID-19","enrollment":""},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT03789292","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-26","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02395055","phase":"PHASE1","title":"Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-06","conditions":"Healthy","enrollment":94},{"nctId":"NCT02762955","phase":"PHASE3","title":"Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-12","conditions":"Psoriasis","enrollment":344},{"nctId":"NCT03607903","phase":"PHASE1, PHASE2","title":"Adalimumab Microneedles in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-07-11","conditions":"Pain, Injection Site","enrollment":24},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02171429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-14","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02163759","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-04","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03823391","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-03-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":48},{"nctId":"NCT03210259","phase":"PHASE3","title":"The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-07-10","conditions":"Psoriasis","enrollment":259},{"nctId":"NCT01166282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Enthesitis Related Arthritis (ERA)","enrollment":46},{"nctId":"NCT01468233","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":326},{"nctId":"NCT01468207","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":307},{"nctId":"NCT00573794","phase":"PHASE3","title":"Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-11-28","conditions":"Ulcerative Colitis","enrollment":592},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02746380","phase":"PHASE3","title":"A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-04-13","conditions":"Arthritis, Rheumatoid","enrollment":383},{"nctId":"NCT02065570","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-05-01","conditions":"Crohn's Disease","enrollment":514},{"nctId":"NCT03172325","phase":"PHASE3","title":"Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2015-11-18","conditions":"Active Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT03927352","phase":"PHASE3","title":"The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-09-05","conditions":"Psoriasis","enrollment":330},{"nctId":"NCT03917628","phase":"PHASE1","title":"Pharmacokinetics and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"Sinocelltech Ltd.","startDate":"2019-05-29","conditions":"Healthy","enrollment":146},{"nctId":"NCT02745080","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-03","conditions":"Psoriatic Arthritis","enrollment":853},{"nctId":"NCT02065622","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-27","conditions":"Ulcerative Colitis (UC)","enrollment":952},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT02065557","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT03849404","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-02-20","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT04439929","phase":"PHASE1","title":"Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects","status":"COMPLETED","sponsor":"Turgut İlaçları A.Ş.","startDate":"2019-07-17","conditions":"Healthy Participants","enrollment":168},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT02871635","phase":"PHASE3","title":"BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-28","conditions":"Crohn Disease","enrollment":147},{"nctId":"NCT02808975","phase":"PHASE4","title":"Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":206},{"nctId":"NCT02489227","phase":"PHASE3","title":"Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2015-08","conditions":"Plaque Psoriasis","enrollment":545},{"nctId":"NCT02497469","phase":"PHASE3","title":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06-29","conditions":"Colitis, Ulcerative","enrollment":771},{"nctId":"NCT03052322","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2017-01-31","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":288},{"nctId":"NCT02696785","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05-02","conditions":"Spondyloarthritis","enrollment":341},{"nctId":"NCT04154852","phase":"PHASE2","title":"ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-06","conditions":"Oligoarthritis","enrollment":22},{"nctId":"NCT04135508","phase":"PHASE3","title":"A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2016-12-13","conditions":"Ankylosing Spondylitis","enrollment":554},{"nctId":"NCT01710358","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":1307},{"nctId":"NCT03014947","phase":"PHASE1","title":"MSB11022 in Healthy Subjects","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":237},{"nctId":"NCT02198651","phase":"PHASE4","title":"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-05","conditions":"Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases","enrollment":149},{"nctId":"NCT01970488","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-10-18","conditions":"Psoriasis","enrollment":350},{"nctId":"NCT02850965","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-17","conditions":"Psoriasis","enrollment":318},{"nctId":"NCT02480153","phase":"PHASE3","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-25","conditions":"Rheumatoid Arthritis","enrollment":597},{"nctId":"NCT01695239","phase":"PHASE3","title":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Psoriasis, Arthritic","enrollment":417},{"nctId":"NCT02499783","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08-17","conditions":"Crohn's Disease","enrollment":205},{"nctId":"NCT02744755","phase":"PHASE3","title":"Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2016-03-31","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT01986127","phase":"PHASE3","title":"Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients","status":"TERMINATED","sponsor":"Sara Varea","startDate":"2014-02-14","conditions":"Crohn's Disease","enrollment":26},{"nctId":"NCT02581345","phase":"PHASE3","title":"Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Chronic Plaque Psoriasis, Psoriasis","enrollment":572},{"nctId":"NCT03273192","phase":"PHASE1","title":"A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-10-22","conditions":"Bioequivalence, Phase 1","enrollment":74},{"nctId":"NCT02187055","phase":"PHASE4","title":"An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08","conditions":"Rhematoid Arthritis","enrollment":1152},{"nctId":"NCT02045979","phase":"PHASE1","title":"Pharmacokinetics and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01-31","conditions":"Healthy","enrollment":327},{"nctId":"NCT02893254","phase":"PHASE3","title":"Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-09-22","conditions":"AS","enrollment":438},{"nctId":"NCT02015793","phase":"PHASE2","title":"Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT01808118","phase":"PHASE3","title":"Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-16","conditions":"Axial Spondyloarthritis","enrollment":673},{"nctId":"NCT02137226","phase":"PHASE3","title":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01-26","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT02019472","phase":"PHASE3","title":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04-04","conditions":"Arthritis, Rheumatoid","enrollment":559},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT02167139","phase":"PHASE3","title":"A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":544}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":534,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7, adalimumab, Humira"],"phase":"phase_3","status":"active","brandName":"Double-blind adalimumab","genericName":"Double-blind adalimumab","companyName":"Abbott","companyId":"abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}